New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
04:55 EDTCMRX, CMRX, CMRX, CMRX, CMRX, CMRX, PFE, PFE, PFE, PFE, PFE, PFE, GILD, GILD, GILD, GILD, GILD, GILD, GSK, GSK, GSK, GSK, GSK, GSK, BMY, BMY, BMY, BMY, BMY, BMY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, AZN, AZN, AZN, AZN, AZN, AZN, SRPT, SRPT, SRPT, SRPT, SRPT, SRPTInternational Society for Antiviral Research to hold a conference
27th International Conference on Antiviral Research to be held in Raleigh, North Carolina on May 12-17.
News For CMRX;PFE;GILD;GSK;BMY;RHHBY;AZN;SRPT From The Last 14 Days
Check below for free stories on CMRX;PFE;GILD;GSK;BMY;RHHBY;AZN;SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
14:56 EDTGILDGilead mentioned cautiously at ISI Group
10:32 EDTAZN, PFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
September 11, 2014
11:58 EDTGILDStocks with call strike movement; DDD GILD
Subscribe for More Information
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
September 9, 2014
10:10 EDTCMRXOn the Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AMC Entertainment (AMC) initiated with a Hold at Topek... AMRI (AMRI) initiated with an Overweight at JPMorgan... Alcoa (AA) initiated with an Outperform at Bernstein... Alumina (AWC) initiated with a Market Perform at Bernstein... American Airlines (AAL) initiated with an Outperform at Credit Suisse... Catalent (CTLT) initiated with a Buy at BofA/Merrill... Chimerix (CMRX) initiated with a Buy at Cantor... Delta Air Lines (DAL) initiated with an Outperform at Credit Suisse... Enable Midstream (ENBL) initiated with an Outperform at BMO Capital... Enbridge Energy (EEP) initiated with a Market Perform at BMO Capital... Endocyte (ECYT) initiated with a Buy at Cantor... EnerNOC (ENOC) initiated with an Outperform at Pacific Crest... Enterprise Products (EPD) initiated with an Outperform at BMO Capital... Good Times Restaurants (GTIM) initiated with a Buy at Roth Capital... JetBlue (JBLU) initiated with an Underperform at Credit Suisse... Kinder Morgan Energy (KMP) initiated with a Market Perform at BMO Capital... MEI Pharma (MEIP) initiated with a Buy at Cantor... ONEOK Partners (OKS) initiated with a Market Perform at BMO Capital... Southwest (LUV) initiated with a Neutral at Credit Suisse... Spectra Energy Partners (SEP) initiated with an Outperform at BMO Capital... TC PipeLines (TCP) initiated with a Market Perform at BMO Capital... TECO Energy (TE) initiated with a Neutral at Citigroup... Targa Resources Partners (NGLS) initiated with a Market Perform at BMO Capital... United Continental (UAL) initiated with an Outperform at Credit Suisse... Weibo (WB) initiated with a Buy at T.H. Capital... Williams Partners (WPZ) initiated with a Market Perform at BMO Capital.
09:34 EDTGILDGilead recently started cutting Sovaldi pricing by 8%, says Cleveland Research
Subscribe for More Information
07:43 EDTCMRXChimerix says data suggest favorable resistance profile for brincidofovir
Subscribe for More Information
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
September 8, 2014
16:06 EDTCMRXChimerix initiated with a Buy at Cantor
Target $33.
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
11:05 EDTGILDOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
09:40 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
08:48 EDTGILD, GSKGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
07:15 EDTPFE, RHHBYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
September 7, 2014
13:57 EDTGSKGlaxoSmithKline Ebola vaccine works in tests on monkeys, Bloomberg says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use